Edition:
United Kingdom

Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

3,758JPY
20 Apr 2018
Change (% chg)

¥34 (+0.91%)
Prev Close
¥3,724
Open
¥3,723
Day's High
¥3,804
Day's Low
¥3,720
Volume
1,253,900
Avg. Vol
2,391,456
52-wk High
¥4,241
52-wk Low
¥2,284

Select another date:

Wed, Apr 4 2018

BRIEF-‍Daiichi Sankyo And Darwinhealth Enter Exclusive Research Collaboration For Novel Cancer Target Initiative​

* ‍DAIICHI SANKYO AND DARWINHEALTH ENTER EXCLUSIVE RESEARCH COLLABORATION FOR NOVEL CANCER TARGET INITIATIVE​

BRIEF-Daiichi Sankyo completes share repurchase

* Says it accumulatively repurchased 15.7 million shares for 50 billion yen in total as of March 22

BRIEF-Fortis Healthcare Gets Court Order Relating To Daiichi Sankyo Co Case

* GETS COURT ORDER RELATING TO DAIICHI SANKYO COMPANY LIMITED CASE

BRIEF-Daiichi Sankyo Initiates Phase 2 Study Of DS-8201

* DAIICHI SANKYO INITIATES PHASE 2 STUDY OF DS-8201 IN PATIENTS WITH HER2-EXPRESSING ADVANCED COLORECTAL CANCER Source text for Eikon: Further company coverage:

BRIEF-Medrx signs joint development contract with DAIICHI SANKYO

* Says it signed a joint development contract with DAIICHI SANKYO COMPANY, LIMITED, regarding development candidates using Nano-sized Colloid Transdermal System owned by the company

BRIEF-Daiichi Sankyo's Regulatory Submission Triggers $20 Mln Milestone Payment To Exelixis​

* CO ‍ANNOUNCES COLLABORATOR DAIICHI SANKYO'S SUBMISSION OF REGULATORY FILING FOR ESAXERENONE (CS-3150) IN JAPAN​

BRIEF-Daiichi Sankyo Initiates Phase 1 Study Of DS-1062 In Patients With Advanced Non-Small Cell Lung Cancer

* DAIICHI SANKYO INITIATES PHASE 1 STUDY OF DS-1062 IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER Source text for Eikon: Further company coverage:

BRIEF-Vernalis has entered into drug discovery collaboration with Daiichi Sankyo

* VERNALIS SAYS ‍HAS ENTERED INTO DRUG DISCOVERY COLLABORATION WITH DAIICHI SANKYO COMPANY, LIMITED UTILIZING VERNALIS' DRUG DISCOVERY PLATFORM​

BRIEF-Daiichi Sankyo And Puma Biotechnology To Collaborate With Major Cancer Center In HER2-Mutated Cancer

* DAIICHI SANKYO AND PUMA BIOTECHNOLOGY ANNOUNCE RESEARCH COLLABORATION WITH MAJOR CANCER CENTER IN HER2-MUTATED CANCER Source text for Eikon: Further company coverage:

BRIEF-R&I affirms Daiichi Sankyo's rating at "AA" and says negative outlook-R&I

* Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA"-R&I

Select another date: